Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Short Interest Down 71.8% in March

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) was the target of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 14,900 shares, a decrease of 71.8% from the March 15th total of 52,800 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 146,500 shares, the days-to-cover ratio is currently 0.1 days.

Shionogi & Co., Ltd. Price Performance

Shionogi & Co., Ltd. stock traded up $0.15 during midday trading on Friday, reaching $8.28. The company's stock had a trading volume of 49,877 shares, compared to its average volume of 131,201. The company has a current ratio of 7.64, a quick ratio of 7.01 and a debt-to-equity ratio of 0.01. The stock has a market cap of $14.09 billion, a PE ratio of 13.11, a price-to-earnings-growth ratio of 2.37 and a beta of 0.21. Shionogi & Co., Ltd. has a 52 week low of $6.22 and a 52 week high of $8.33. The business has a 50-day moving average price of $7.59 and a 200-day moving average price of $7.21.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) last released its quarterly earnings data on Friday, January 31st. The company reported $0.16 earnings per share (EPS) for the quarter. Shionogi & Co., Ltd. had a net margin of 35.53% and a return on equity of 12.02%. On average, sell-side analysts predict that Shionogi & Co., Ltd. will post 0.66 EPS for the current year.

Shionogi & Co., Ltd. Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.